BRAF and K-RAS mutation in a Greek papillary and medullary thyroid carcinoma cohort

Anticancer Research

Volumn 28, Issue 1 A, 2008, Pages 305-308

  Goutas, Nikolaos ^a   Vlachodimitropoulos, Dimitrios ^a   Bouka, Myrto ^b   Lazaris, Andreas C ^b   Nasioulas, George ^c   Gazouli, Maria ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c HYGEIA HOSPITAL   (Greece)

Author keywords

BRAF; K RAS; Medullary; Mutation; Papillary; Thyroid carcinoma

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CANCER STAGING; CHILD; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; INFANT; MALE; NEWBORN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

ADULT; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; FEMALE; GENES, RAS; GREECE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 40549135970     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Hundahl SA, Fleming ID, Fremgen AM and Menck HR: National cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83: 2638-2648, 1998.
2. Bongarzone I and Pierotti MA: The molecular basis of thyroid epithelial tumorigenesis. Tumori 89: 514-516, 2003.
3. Tallini G: Molecular pathobiology of thyroid neoplasms. Endocr Pathol 13: 271-288, 2002.
4. McIver B, Grebe SK and Eberhardt NL: The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord 4: 221-234, 2004.
5. Vasko V, Ferrand M, Di Cristofaro J, Carayon P, Henry JF and de Micco C: Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab 88: 2745-2752, 2003.
6. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH and Nikiforov YE: Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120: 71-77, 2003.
7. Clayman GL and el-Baradie TS: Medullary thyroid cancer. Otolaryngol Clin North Am 36: 91-105, 2003.
8. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C, Eng C and Freiburg-Warsaw-Columbus Pheochromocytoma Study Group: Germline mutations in nonsyndromic pheochromocytoma. N Engl J Med 346: 1459-1466, 2002.
9. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95: 625-627, 2003.
10. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA and Nikiforov YE: Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94-101, 2005.
11. Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262, 2005.
12. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA and Nikiforov YE: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399-5404, 2003.
13. Kahn SM, Jiang W, Culbertson TA, Weinstein IB, Williams GM, Tomita N and Ronai Z: Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene 6: 1079-1083, 1991.
14. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K Kambara T, MacPhee DG, Young J, Leggett BA, Jass JR, Tanaka N and Matsubara N: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22: 4584-4594, 2004.
15. Karga H, Lee JK, Vickery AL, Thor A, Gaz R and Jameson JL: RAS oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab 73: 832-836, 1991.
16. Figge L: Molecular pathogenesis of thyroid cancer. In: Thyroid Cancer: A Comprehensive Guide to Clinical Management. Wartofsky L. (ed.). Humana Press, Totowa New Jersey, pp. 57-75, 2000.
17. Bockhorn M, Frilling A, Kalinin V, Schrader S and Broelsch CE: Absence of H- and K-ras oncogene mutations in sporadic medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 108: 49-53, 2000.
18. Moley JF, Brother MB, Wells SA, Spengler BA, Biedler JL and Brodeur GM: Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res 51: 1596-1599, 1991.
19. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutation in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signalling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454-1457, 2003.
20. Namba H, Rubin SA and Fagin JA: Point mutation of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol 4: 1474-1479, 1990.
21. ManentiG, Pilotti S, Re FC, Della Portaa G and Pierotti MA: Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinoma. Eur J Cancer 30A: 987-993, 1994.
22. V599Ins). Clin Endocrinol 64: 105-109, 2006.
23. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW and Sidransky D: BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrin Metab 89: 1365-1368, 2004.
24. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T and Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88: 4393-4397, 2003.
25. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J and Tallini G: Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 21: 3226-3235, 2003.
26. Capella G, Matias-Guiu X, Ampudia X, de Leiva A, Perucho M and Prat J: Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues. Diagn Mol Pathol 5: 45-52, 1996.